Business & Finance
BioArctic swings to profit in Q3 2018
9 November 2018 -

BioArtic AB (STO:BIOAB), a research-based biopharmaceutical company, on Thursday reported profit of SEK25.9m, or EPS SEK0.29, for the third quarter 2018, from 1 July 2018 to 30 September 2018.

This was an improvement over loss of SEK0.1m, or SEK0.00 per share, in Q3 2017.

Net revenues for the quarter amounted to SEK94.0m, as compared SEK31.5m on Q3 2017.

BioArctic is focused on disease modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. The company also develops a treatment for complete spinal cord injury.